Summary results of clinical trials soon to be available to the public
The European Medicines Agency has launched a new version of the European Clinical Trials Database (EudraCT). This new version, EudraCT V9, marks the initial step of a process through which summary clinical trial results will be made publicly available through the EU Clinical Trials Register (EU CTR).
EudraCT already contains protocol-related information submitted by sponsors for interventional clinical trials conducted in European Economic Area countries and/or in third countries, when the clinical trial is part of an agreed Paediatric Investigation Plan (PIP). As of today, clinical-trial sponsors are encouraged to register on the EudraCT website to start uploading summary results. Results posted by sponsors in EudraCT will start to become publicly available once the Agency has launched the complementary new version of the EU CTR towards the end of the year. The content and level of detail of the summary results is set out in a European Commission guideline and in its technical guidance.
This initial release of EudraCT will be followed by further updates to the system in 2014 which will provide improved functionalities for sponsors and EU regulatory authorities. With the launch of these further iterations of EudraCT by mid-2014, the modalities and timing of posting of result-related information as described in the EC guideline will apply, and sponsors will then be required to post result-related information.
The Agency supports international standardisation of data requirements for clinical trial registration. EudraCT’s data requirements are already substantially aligned with those of ClinicalTrials.gov and the Agency works closely with the National Institutes of Health (NIH) of the United States, which operate ClinicalTrials.gov and with stakeholders to progress this objective.
The Agency will make the data descriptions and technical specifications available to enable stakeholders to build systems that can generate structured data sets and upload them electronically into EudraCT.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.